A naukri.com initiative
Bioengineer
2w
60
Image Credit: Bioengineer
Moffitt to Unveil Plenary and Late-Breaking Findings on Blood, Melanoma, and Brain Metastases at ASCO 2025
- The Moffitt Cancer Center will present significant findings at the 2025 ASCO Annual Meeting, focusing on blood disorders, melanoma, and brain metastases.
- Key presentations include the VERIFY study on polycythemia vera, exploring rusfertide's therapeutic potential in controlling erythrocytosis with fewer side effects.
- Research on melanoma involves investigating immunotherapeutic combinations like neoadjuvant pembrolizumab monotherapy versus its combination with vidutolimod.
- A pivotal trial examines regimens for BRAFV600-mutant melanoma brain metastases, aiming to optimize systemic therapies that breach the blood-brain barrier.
- Studies on renal cell carcinoma explore promising combinations involving the RET kinase inhibitor zanzalintinib alongside immune checkpoint inhibitors.
- In head and neck squamous cell carcinoma, an investigation on ficerafusp alfa combined with pembrolizumab aims to enhance immune infiltration and checkpoint inhibitor activity.
- Moffitt's commitment to Merkel cell carcinoma includes a phase II trial combining lenvatinib with pembrolizumab to improve treatment efficacy.
- Research on tumor-infiltrating lymphocyte therapy in metastatic melanoma aims to refine cell therapy manufacturing and patient selection for personalized immunotherapy approaches.
- A presentation highlights the contributions of international medical graduates within ASCO's framework, emphasizing diversity's impact on research, education, and patient care.
- Moffitt's research at ASCO 2025 symbolizes groundbreaking efforts to translate deep molecular insights into actionable treatments, with a focus on precision medicine and collaborative innovation.
- The multidisciplinary expertise of Moffitt, coupled with scientific rigor and patient-centric care models, positions it as a leader in oncology research and clinical innovation.
Read Full Article
3 Likes
For uninterrupted reading, download the app